Debiopharm, an independent biopharmaceutical company based in Switzerland, has forged a collaborative partnership with USA’s ThinkingNodeLife.ai (TNL), a pioneer in AI Digital Cells Lab, to advance the development of a cutting-edge cancer drug. This strategic alliance combines TNL’s AI Digital Cells Lab platform with Debiopharm’s extensive pharmaceutical expertise, marking a significant leap in oncology drug […]
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the United States Food and Drug Administration (USFDA) for its Cyclophosphamide Capsules USP, available in 25 mg and 50 mg dosages. This approval represents a major advancement in the field of oncology, as Cyclophosphamide is a key chemotherapy […]
Evive Biotech, a global biopharmaceutical company and a subsidiary of Yifan Pharmaceutical Co. Ltd., along with New Jersey-based Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo Pharma USA Inc., announced the U.S. Food and Drug Administration (FDA) approval of Ryzneuta (Efbemalenograstim alfa). The medication is indicated to decrease the incidence of infection as manifested by febrile […]
ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio Limited to evaluate a series of drug candidates for cancer therapy. The collaboration focuses on an innovative series of molecules developed by StingRay, designed to target kinases linked to cancer. Innovative Approach in Oncology Drug Development Under […]
Leading global contract research organization, Crown Bioscience, has unveiled OrganoidXplore, a trailblazing service offering in the domain of preclinical oncology research. This state-of-the-art platform promises to facilitate robust and clinically relevant screenings at unprecedented speeds, marking a significant advancement in cancer treatment development. Ground-Breaking Organoid Panel Screening Accelerates Oncology Research OrganoidXplore stands out with its […]
In a significant development for its oncology portfolio in South Eastern Europe, Venus Remedies Ltd has been granted marketing authorization from Serbia for chemotherapy drugs gemcitabine and docetaxel. This approval takes the company’s total marketing authorizations for oncology products to 511 across 66 countries. It marks another crucial step toward Venus Remedies’ ambition of becoming […]
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced RET-mutant medullary thyroid cancer (MTC). The Phase 3 clinical trial distinctly highlights Retevmo’s superiority over existing first-line treatments, namely multikinase inhibitors cabozantinib and vandetanib. Retevmo demonstrated a statistically significant and […]
ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of its international Phase 1 ENBOLDEN-101 trial enrollment. The trial aims to investigate the safety and efficacy of ENB-003, the company’s lead product, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). This Phase 1/2a study is an open-label, […]
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer. The approval applies to patients who have undergone prior systemic therapy in a metastatic setting or experienced disease recurrence within six […]
the International Agency for Research on Cancer (IARC) and the Joint Expert Committee on Food Additives (JECFA), of the World Health Organization (WHO) and the Food and Agriculture Organization (FAO), issued assessments regarding the health impacts of the non-sugar sweetener aspartame. These agencies cited limited evidence linking aspartame to carcinogenicity in humans, leading to IARC […]
